共 10 条
[1]
AMES MM, 1979, CANCER RES, V39, P5016
[3]
DINCALCI M, 1978, CANCER TREAT REP, V62, P2117
[4]
INFLUENCE OF ASCITES ON THE PHARMACOKINETICS OF HEXAMETHYLMELAMINE AND N-DEMETHYLATED METABOLITES IN OVARIAN-CANCER PATIENTS
[J].
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY,
1981, 17 (12)
:1331-1335
[5]
DUBOIS J, 1986, CANCER CHEMOTH PHARM, V18, P226
[6]
THE ROLE OF HEXAMETHYLMELAMINE IN THE COMBINATION CHEMOTHERAPY OF ADVANCED OVARIAN-CANCER - A COMPARISON OF HEXAMETHYLMELAMINE, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN (H-CAP) VERSUS CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN (CAP)
[J].
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS,
1990, 13 (05)
:410-415
[7]
MILLER KJ, 1985, CANCER CHEMOTH PHARM, V15, P49
[8]
MORIMOTO M, 1980, CANCER RES, V40, P2762
[10]
SELEN A, 1991, PHARM BIOEQUIVALENCE, P137